Table 1. Overview of randomized controlled trials.

Study (year of publication)	Country	Inclusion criteria	Syntax score mean (≥33)	Number of vessels diseased	Patients assigned		Mean age (years)	Male gender	Medically treated diabetes (on insulin)	Stents used	Median follow-up (years)
Study (year of publication)	Country	Inclusion criteria	Syntax score mean (≥33)	Number of vessels diseased	CABG	DES-PCI	Mean age (years)	Male gender	Medically treated diabetes (on insulin)	Stents used	Median follow-up (years)
CARDia, 2010 (16)	United Kingdom and Ireland	Diabetics with multivessel disease including PLAD	NR	3VD: 63% 2VD: 32% PLAD: 5%	242	248	64	74%	100% (38%)	SES (69%) BMS (31%)	1
FREEDOM, 2012 (17)	Multinational	Diabetes and stenosis of more than 70% in two or more major epicardial vessels	26 (19%)	3VD: 83% 2VD: 17%	947	953	63	71%	100% (32%)	SES (51%) PES (43%)	3.8
VA CARDS, 2013 (18)	US	Diabetics with multivessel disease including PLAD	22 (13%)	3VD: 63% 2VD: 24% PLAD: 13%	97	101	62	99%	100% (47%)	SES (20%) PES (35%) EES (18%) ZES (2%) MIXED (16%) BMS (1%)	2
SYNTAX*, 2014 (15)	Multinational	Significant stenosis in vessels supplying all three major epicardial territories	28, NR	3VD: 100% 2VD: 0%	549	546	64	80%	27% (11%)	PES	5
BEST TRIAL, 2015 (13)	South Korea, China, Malaysia, and Thailand	Stenosis of more than 70% of the vessel diameter in major epicardial vessels in the territories of at least two coronary arteries	24 (16%)	3VD: 77% 2VD: 23%	442	438	64	72%	41% (4%)	EES	2

*, subgroup analysis. 3VD, three-vessel disease; 2VD, two-vessel disease; PLAD, proximal left anterior descending artery disease; DES-PCI, drug-eluting stent percutaneous coronary intervention; CABG: coronary artery bypass grafting; BMS, bare-metal stent; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus eluting stent; NR, not reported.